The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient

Mara Lorenzi1

  • 1Schepens Eye Research Institute and Department of Ophthalmology, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, USA. mara.lorenzi@schepens.harvard.edu

Insights

The polyol pathway, linked to diabetic complications, shows promise for treating diabetic retinopathy. New aldose reductase inhibitors may reveal its true role in the disease.

Area of Science:

  • Biochemistry and Metabolism
  • Endocrinology and Diabetes
  • Ophthalmology

Background:

  • The polyol pathway, converting glucose to sorbitol and then fructose, is implicated in diabetic hyperglycemia's cellular toxicity.
  • Its enzymes are present in tissues affected by diabetic complications, and pathway products induce cellular stress.
  • Aldose reductase, the rate-limiting enzyme, inhibition prevents retinopathy in rodent models, but clinical trials yielded disappointing results.

Purpose of the Study:

  • To re-evaluate the polyol pathway's role in diabetic retinopathy given new insights.
  • To explore the potential of novel aldose reductase inhibitors for future clinical trials.

Main Methods:

  • Review of existing literature and experimental findings on the polyol pathway and diabetic retinopathy.
  • Analysis of recent discoveries including glial/neuronal abnormalities and aldose reductase in retinal endothelial cells.
  • Consideration of genetic polymorphisms in the aldose reductase gene associated with retinopathy susceptibility.

Main Results:

  • Previous clinical trial results for aldose reductase inhibition were disappointing, suggesting limitations in current indicators of pathway activity.
  • New evidence points to glial and neuronal involvement in diabetic retinopathy mediated by the polyol pathway.
  • Aldose reductase gene polymorphisms correlate with diabetic retinopathy risk and progression.

Conclusions:

  • Despite past setbacks, renewed interest in the polyol pathway's role in diabetic retinopathy is warranted.
  • Development of highly effective and safe aldose reductase inhibitors is crucial for future therapeutic exploration.
  • Further research is needed to determine if the polyol pathway's resilience indicates an undiscovered role in human diabetic retinopathy.

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...